Sakar Healthcare could break out above ₹375, with ₹324 as the support level on a closing basis, backed by strong charts and recent EU drug approvals, says SEBI RA Gunjan Kumar. The company posted its highest profit and revenue in 13 quarters. FIIs and DIIs raised their stakes recently. The stock is up over 45% in three months.